CollPlant Biotechnologies Ltd.

Welcome to the Cold Plant Biotechnologies Investor Conference Call to discuss financial results for the full year 2022 and corporate updates. The question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. Now, I'd like to turn the call over to Dori Kurowski of LifeSci Advisors. Please go ahead, ma'am.

Good morning. I would like to welcome everyone to Cold Plant Biotechnologies' first financial results conference call. for the full year ended December 31st, 2022. With us on the call today from Coal Plant are Yahil Tal, Chief Executive Officer, who will provide an overview of the company's programs and forthcoming updates. And Aran Rotem, Chief Financial Officer, who will provide a summary of Coal Plant's financial results for the full year ending December 31st, 2022. Before we get started, I would like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the Risk Factors section of COLE Plans filings with the Securities and Exchange Commission, which can be found at www.sec.gov. or on Cold Plants' website at www.coldplants.com. In addition, any forward-looking statements made on this call represent Cold Plants' views only as of today, March 29, 2023, and should not be relied upon as representing the company's views as of any subsequent date, and Cold Plant Management specifically disclaims any obligation to update or revise any of these forward-looking statements. With that, let me turn the call over to Yehiel Tal, Chief Executive Officer of Coal Plant Biotechnologies. Please go ahead, sir.

Good morning, everyone. We are very pleased to have you join us today on Coal Plant's very first investor conference call to discuss the 2022 financial results and corporate developments. Since this is the first call with investors, we wanted to remind you about the mission of our company. Copland is developing and delivering collagen technology and regenerative medicine products to improve and prolong life. And now, imagine a future where there will be an unlimited supply of spare parts for the human body, including life-saving organs. And also imagine that in the future, medical treatment will be tailored for the individual characteristics of each patient. And then also imagine that drugs will be developed without the need for animal testing. We at Cold Plant aspire to become the leaders in regenerative medicine, helping people live longer and better and creating improvements in science, through our regenerative technology. Since being a NASDAQ listed in 2018, we have drawn on the collective strength of our company management in regenerative medicine, medical devices, and engineering, as well as our strong IP position, human capital, and partnerships to derive the company's value and innovation and become market leader in regenerative and aesthetic medicine. Collagen is the primary scaffolding molecule in the body's connective tissues and organs, and it is our goal to become global leader in regenerative medicine by applying our non-animal derived recombinant human collagen, or Rh collagen, to novel medical and aesthetic products. Let's move to recent developments that relate to our novel program that rely on Rh collagen technology. The first category that we are applying our technology is in a static medicine with our dermal filler product candidates. Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to move forward according to plan. Per the agreement, Cold Plant has the potential to receive additional milestones and option payments regarding the two products that we are developing and will receive royalties on any product sales should we obtain approval. AbbVie continues to advance the filler program and Cold Plant expects that the first of these milestones could be achieved in 2023. In addition, we are moving forward with a third generation photocurable dermal and soft tissue filler. Our goal with the development of this filler is to create a product with three capabilities, lifting capacity, regeneration of new tissue, and contouring capabilities. Recently, we generated additional supporting data from a 12-month pivotal preclinical study of this filler, demonstrating superior tissue regeneration, lifting capacity, and volume retention compared to the industry gold standard. This promising result, combining the regenerative properties of collagen and the advantages of photocuring technology, position ColdPlant's product candidate as a revolutionary platform technology with the potential to create a paradigm shift in the evolving medical aesthetic market. We believe that this third-generation filler has the potential to be highly competitive by providing both refined and natural-looking aesthetic results as well as uniquely regenerative long-term benefits. Orkland has granted its global pharmaceutical partner, AbbVie, the right of first negotiation to obtain a worldwide exclusive license to this product candidate. Our second area of focus is regenerative aesthetics with our regenerative breast implant program. Earlier this year, we announced positive results from a preclinical study evaluating our regenerative implants in a large animal model. Results from this study demonstrated progressive stages of tissue regeneration after three months as highlighted by the formation of maturing connective tissue and neovascular networks within the implants with no adverse events reported. No regenerative breast implant currently exists in the market and these implants would be the first of their kind also having beneficial regenerative properties. Importantly, since these implants are made of our Rh collagen and other biomaterials versus animal-derived collagen, there is less chance of rejection by the body or what is known as acute rejection. According to the US Food and Drug Administration, approximately 350,000 Americas have reported adverse events involving breast implants between 2009 and 2019. Reports range from autoimmune symptoms to breast implant associated anaplastic large cell lymphoma. Cold plant implants are expected to regenerate breast tissue without eliciting immune response and thus may provide a revolutionary alternative for both aesthetic and reconstructive procedures, including post-masectomy for cancer patients. Later this year, we plan to initiate another study in large animals with commercial-sized implants to generate additional safety data in support of commercialization, and we look forward to reporting results of that study. We also made a decision to strategically expand into personalized medicine, and we signed a collaboration agreement in November 2022 with Tel Aviv University and Sheba Medical Hospital for our Got on a Chip program. Our agreement with these two research institutions is to co-develop bioprinted human intestine model for drug discovery and personalized treatment of ulcerative colitis. The 3D bioprinted model is designed to emulate the human intestine tissue in order to allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes. We expect that this approach could be groundbreaking improvement over existing use of animal models CorePlant will have the right to commercialize the product once ready to market. Now, let me turn to our commercial portfolio of BioInks, which is another program of ours that falls within our focused area of regenerative medicine. We expanded our commercial portfolio of collagen-based BioInks with two new products, including CoLink 3D90 which offers increased mechanical properties and CoLink 3D50L with our first BioInk available in powder form to provide enhanced operational flexibility. Our BioInk platform, which was established in 2021 with the launch of CoLink 3D50, allows our biopharma and academia customers to streamline their process of new product development by utilizing animal-free alternatives that delivers improved bio functionality, safety, and reproducibility. ColdPlant remains engaged in partnering discussions with several industry leaders and academic institutions interested in the company's technology and expertise in 3D bioprinting to develop therapeutics and medical applications. We are confident that our collaboration with a worldwide pharmaceutical leader, as well as other numerous collaborations and partnership agreements, has validated our technology and its multiple areas of applicability. We have also made strides in developing a proprietary aseptic process to mass produce sterile collagen. The sterile collagen will serve as an ideal substrate for stem cells, induced pluripotent stem cells, and all kinds of primary human cells. It will also address production processes where collagen as major constituent should be sterile. And now I will turn the call over to our Deputy CEO and Chief Financial Officer, Ron Rotem, to provide a recap of our financial results. Eran?